A biotech firm has announced trials for a dog implant that mimics the weight-loss drugs taken by humans, raising hopes for tackling pet obesity but also prompting warnings from veterinary experts. The implant, called OKV-119, contains a GLP-1 mimic called exenatide, which suppresses appetite. The company, Okava, aims to bring it to the market as soon as 2028.
Dr Eleanor Raffan, a veterinary surgeon and expert in canine genetics and obesity at the University of Cambridge, advised owners to first try modifying their dog's diet and exercise regime, as that is known to be safe and effective. However, she added that if that fails, using GLP-1 mimic drugs could be a reasonable option, provided they are tested in proper, randomised clinical trials.
One major concern is that appetite loss in pets can be a sign of illness. Raffan warned that if cats stop eating for a few days, they can develop a life-threatening condition called hepatic lipidosis. Michael Klotsman, CEO of Okava, said behavioural changes from the implant would be different from illness, with pets eating appropriate portions without excessive begging.
According to a 2024 report by UK Pet Food, 50% of dogs and 43% of cats are overweight. Excess weight can shorten lifespan and lead to problems such as diabetes, arthritis and cancer. The implant could help owners resist 'pester power' from food-obsessed dogs, but experts urge caution until proper trials are completed.
